Amikacin plus ceftazidime versus amikacin plus piperacillin versus amikacin plus aztreonam in infections in neoplastic patients with granulocytopenia

Chemioterapia. 1987 Dec;6(6):440-4.

Abstract

Sixty granulocytopenic patients (granulocytes less than 1000/mm3) affected with solid tumors, previously submitted to antiblastic therapy and with infections, were treated with three antibiotic combinations: amikacin + ceftazidime, amikacin + piperacillin or amikacin + aztreonam. In 68% of the cases the infections were due to gram-negative and in the remaining 32% to gram-positive microorganisms. The results obtained with the three treatments show a slight but significant statistical difference (p less than 0.05), due to the greater efficacy of the amikacin + ceftazidime combination on gram-positive and amikacin + aztreonam on gram-negative bacteria.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Agranulocytosis / complications*
  • Amikacin / therapeutic use*
  • Anti-Bacterial Agents / therapeutic use*
  • Aztreonam / therapeutic use
  • Bacterial Infections / drug therapy*
  • Bacterial Infections / etiology
  • Ceftazidime / therapeutic use
  • Drug Therapy, Combination
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasms / complications*
  • Piperacillin / therapeutic use
  • Random Allocation

Substances

  • Anti-Bacterial Agents
  • Amikacin
  • Ceftazidime
  • Aztreonam
  • Piperacillin